<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872078</url>
  </required_header>
  <id_info>
    <org_study_id>D5320C00001</org_study_id>
    <nct_id>NCT01872078</nct_id>
  </id_info>
  <brief_title>A Study of AZD4901 in Females With Polycystic Ovary Syndrome</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of AZD4901 when given in multiple doses to females with Polycystic
      Ovary Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline at Day 7 in Luteinizing hormone AUC(0-8)</measure>
    <time_frame>Day-1 and Day7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, physical exam, vital signs, ECGs, clinical laboratory safety tests C-SSRS)</measure>
    <time_frame>Up to 85 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Day 7 (free and total testosterone)</measure>
    <time_frame>Baseline (Day -1) to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Day 28 (free and total testosterone)</measure>
    <time_frame>Baseline (Day -1) to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: tmax, AUC(0-8 hours), Cmin, and Cmax)</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: tmax, AUC(0-8hours), Cmin, and Cmax)</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between different plasma exposures/doses of AZD4901 and clinical response as measured by changes in LH and testosterone concentrations</measure>
    <time_frame>Baseline (Day -1) to Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>A mathematical model that describes the AZD4901 plasma concentration time profile, LH and testosterone concentration and the mathematical relation between AZD4901 plasma concentration and LH and testosterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-β-OH cholesterol ratio of post treatment:pre treatment concentration</measure>
    <time_frame>Baseline (Day -1) to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-β-OH testosterone ratio of post treatment:pre treatment concentration</measure>
    <time_frame>Baseline (Day -1) to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: the ratio of active metabolite Cmax to AZD4901 Cmax)</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: the ratio of active metabolite AUC(0-8) to AZD4901 AUC(0-8))</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: the ratio of active metabolite Cmax to AZD4901 Cmax)</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD4901 and its active metabolite multiple dose pharmacokinetics profile in plasma (PK parameters: the ratio of active metabolite AUC(0-8) to AZD4901 AUC(0-8))</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder</condition>
  <arm_group>
    <arm_group_label>AZD4901 20 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD4901 20 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4901 20mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD4901 20mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4901 40 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD4901 40 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match AZD4901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4901 (oral)</intervention_name>
    <description>Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg  twice a day, AZD4901 40 mg twice a day or placebo</description>
    <arm_group_label>AZD4901 20 mg once a day</arm_group_label>
    <arm_group_label>AZD4901 20mg twice a day</arm_group_label>
    <arm_group_label>AZD4901 40 mg twice a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match AZD4901</intervention_name>
    <description>Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg  twice a day, AZD4901 40 mg twice a day or placebo</description>
    <arm_group_label>Placebo to match AZD4901</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for
        cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2
        (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea
        (defined as ≤ 6 menses per year). Negative serum pregnancy test at screening. Negative
        urine pregnancy test before randomisation. Not be breast-feeding. Not have been pregnant
        within the 6 months prior to screening.

        Exclusion Criteria:

        Perimenopausal or reached natural menopause, defined as FSH &gt; 10 IU/L. Menstruated within
        the month prior to the baseline visit. Hysterectomy or bilateral oophorectomy or both.
        Clinically relevant disease and abnormalities (past or present), and in particular causes
        of abnormal vaginal bleeding.

        Withdrawals from oral contraceptives if their LH levels are below 3 IU/L when retested
        within 7 ± 1 days of the baseline visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyothis George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information</last_name>
    <phone>800-236-9933</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Information Outside US</last_name>
    <phone>001-800-236-9933</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <state>Nothern Irelind</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics, Pharmacodynamics, endocrinopathies, PCOS, female, hormone, LH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
